Showing posts with label Delta Variant. Show all posts
Showing posts with label Delta Variant. Show all posts

Monday, September 6, 2021

New Zealand lifts virus curbs, says Delta elimination in sight

WELLINGTON - New Zealand Prime Minister Jacinda Ardern on Monday said nationwide coronavirus curbs would be lifted, bar in the biggest city of Auckland, as the country gets on top of an outbreak of the Delta variant.

New Zealand had been largely virus-free, excluding a small cluster of cases in February, until an infected traveler from Australia seeded an outbreak that prompted Ardern to impose the national lockdown last week.

Ardern, who said restrictions would be eased outside of Auckland from Wednesday, is continuing to pursue an elimination strategy for the disease.

"We are within sight of elimination, but we can't drop the ball," Ardern said at a televised news conference. "Day by day we are making very good progress. What I don't want to do is move too quickly and then see a resurgence."

About 1.7 million people in greater Auckland, the epicenter of the outbreak, will remain in a full level 4 lockdown until at least Sept. 14.

The easing of the alert status to level 2 from level 3 in the rest of the country will allow the reopening of schools, offices and businesses. Regional travel will also be allowed.

Face masks will still be required inside most public venues, including shops and malls. Indoor hospitality venues will be limited to 50 patrons and outdoor venues to 100 people.

Daily new cases in the current outbreak have dropped from a peak of 85 on Aug. 29 to 20 on Monday.

The current outbreak is responsible for 821 of the country's total of about 3,400 COVID-19 cases since the start of the pandemic. It has reported 27 deaths.

Ardern's tough lockdowns and international border closure helped rein in COVID-19, but the government now faces questions over a delayed vaccine rollout and rising costs in a country heavily reliant on an immigrant workforce.

Just about 30% of the country's 5.1 million people has been fully vaccinated, the slowest pace among the wealthy nations of the OECD grouping. (Reporting by Praveen Menon; Editing by Clarence Fernandez and Jane Wardell)

-reuters

Tuesday, August 24, 2021

Israel's COVID-19 vaccine boosters show signs of taming Delta

JERUSALEM - Less than a month into a COVID-19 vaccine booster drive, Israel is seeing signs of an impact on the country's high infection and severe illness rates fueled by the fast-spreading Delta variant, officials and scientists say.

Delta hit Israel in June, just as the country began to reap the benefits of one of the world's fastest vaccine roll-outs.

With an open economy and most curbs scrapped, Israel went from single-digit daily infections and zero deaths to around 7,500 daily cases last week, 600 people hospitalized in serious condition and more than 150 people dying in that week alone.

On July 30, it began administering a third dose of the Pfizer/BioNtech vaccine to people over 60, the first country to do so. On Thursday it expanded eligibility to 40-year-olds and up whose second dose was given at least 5 months prior, saying the age may drop further.

In the past 10 days, the pandemic is abating among the first age group, more than a million of whom have received a third vaccine dose, according to Israeli health ministry data and scientists interviewed by Reuters.

The rate of disease spread among vaccinated people age 60 and over - known as the reproduction rate - began falling steadily around Aug. 13 and has dipped below 1, indicating that each infected person is transmitting the virus to fewer than one other person. A reproduction rate of less than 1 means an outbreak is subsiding.

Scientists said booster shots are having an impact on infections, but other factors are likely contributing to the decline as well.

"The numbers are still very high but what has changed is that the very high increase in the rate of infections and severe cases has diminished, as has the pace at which the pandemic is spreading," said Eran Segal, data scientist at the Weizmann Institute of Science and an adviser to the government.

"This is likely due to the third booster shots, an uptake in people taking the first dose and the high number of people infected per week, possibly up to 100,000, who now have natural immunity," Segal said.

BOOSTER VS LOCKDOWN

After reaching one of the highest per-capita infection rates in the world this month, the question now is whether Israel can battle its way out of a fourth outbreak without imposing another lockdown that would damage its economy.

Evidence has emerged showing that while the vaccine is still highly effective in preventing serious illness, its protection diminishes with time. But there is no consensus among scientists and agencies that a third dose is necessary, and the World Health Organization has said more of the world should be vaccinated with a first dose before people receive a third dose.

The United States has announced plans to offer booster doses to all Americans, 8 months after their second vaccine dose, citing data showing diminishing protection. Canada, France and Germany have also planned booster campaigns.

About a million of Israel's 9.3 million population have so far chosen not to vaccinate at all and children under 12 are still not eligible for the shots. On Thursday, health officials said they have identified waning immunity among people under 40, although relatively few have fallen seriously ill.

According to Doron Gazit, a member of the Hebrew University's COVID-19 expert team which advises government, the rise in cases of severely ill vaccinated people in the 60 and older group has been steadily slowing to a halt in the last 10 days.

"We attribute this to the booster shots and to more cautious behavior recently," Gazit said.

More than half of those over 60 have received a third jab, according to the Health ministry.

The rate of new severe cases among unvaccinated patients 70 and older is now 7 times that of vaccinated patients, and the gap will continue to grow as long as infections rise, according to Gazit. Among those over 50, that gap is 4-fold.

"We are optimistic, but very cautious," Israeli Health Minister Nitzan Horowitz told public broadcaster Kan on Sunday. "It gives us more time, slows the spread and we're moving away from lockdown."

But even if the boosters are slowing the pandemic's pace, it is unlikely to fend Delta off entirely.

Dvir Aran, biomedical data scientist at Technion - Israel's Institute of Technology, said that while cases are retreating, other measures are needed alongside boosters to stop the pandemic. 

"It will take a long time until enough people get a third dose and until then thousands more people will getting seriously ill," Aran said.

Since Delta's surge, Israel has reimposed indoor mask wearing, limitations on gatherings and ramped up rapid testing.

Its "living with COVID" policy will be tested come September, when schools reopen after summer break and when the Jewish holiday season starts, with families traditionally gathering to celebrate.

-reuters

Thursday, August 19, 2021

British study shows COVID-19 vaccine efficacy wanes under Delta

A British public health study has found that protection from either of the two most commonly used COVID-19 vaccines against the now prevalent Delta variant of the coronavirus weakens within three months.

It also found that those who get infected after receiving two shots of either the Pfizer-BioNTech or the AstraZeneca vaccine may be of greater risk to others than under previous variants of the coronavirus.

Based on more than three million nose and throat swabs taken across Britain, the Oxford University study found that 90 days after a second shot of the Pfizer or Astrazeneca vaccine, their efficacy in preventing infections had slipped to 75% and 61% respectively.

That was down from 85% and 68%, respectively, seen two weeks after a second dose. The decline in efficacy was more pronounced among those aged 35 years and older than those below that age.

"Both of these vaccines, at two doses, are still doing really well against Delta... When you start very, very high, you got a long way to go," said Sarah Walker, an Oxford professor of medical statistics and chief investigator for the survey.

Walker was not involved in work on AstraZeneca's vaccine, which was initially developed by immunology experts at Oxford.

The researchers would not project how much more the protection would drop over time, but suggested that the efficacy of the two vaccines studied would converge within 4-5 months after the second shot.

VIRAL LOAD

Highlighting the increased risk of contagion from the Delta variant, the study also showed that those who do get infected despite being fully vaccinated tend to have a viral load similar to the unvaccinated with an infection, a clear deterioration from when the Alpha variant was still dominant in Britain.

The Oxford findings are in line with an analysis by the U.S. Centers for Disease Control and Prevention (CDC) and come as the U.S. government outlines plans to make COVID-19 vaccine booster shots widely available next month amid a rise in Delta variant infections. It has cited data indicating diminishing protection from the vaccines over time.

Israel began administering third Pfizer doses last month to confront a surge in local infections driven by Delta. Several European countries are also expected to begin offering boosters to the elderly and people with weak immune systems.

Pfizer has said its vaccine's efficacy drops over time. Last month AstraZeneca said it was still looking into how long its vaccine's protection lasts and whether a booster dose would be needed to keep up immunity.

"The fact that we do see ... more viral load hints (...) that indeed herd immunity might become more challenging," said co-author Koen Pouwels, also of Oxford University.

Herd immunity is when a large enough portion of the population is immune to a pathogen, either by vaccination or prior infection, stopping infection numbers from growing.

"Vaccines are probably best at preventing severe disease and slightly less at preventing transmission," said Pouwels.

The authors cautioned that the viral concentration in the throat was only a rough proxy for severity of symptoms and that they had no new data on the duration of infections.

The survey, which has yet to be peer-reviewed before publication in a scientific journal, underscores concerns by scientists that the Delta variant, first identified in India, can infect fully vaccinated people at a greater rate than previous lineages, and that the vaccinated could more easily transmit it.

To contrast periods before and after Delta became prevalent, the Oxford researchers analyzed about 2.58 million swabs taken from 380,000 randomly picked adults between Dec. 1, 2020, and May 16, 2021, and 810,000 test results from 360,000 participants between May 17 and Aug. 1.

The study was conducted in partnership with Britain's Office of National Statistics (ONS) and the Department for Health and Social Care (DHSC).

-reuters

Saturday, August 7, 2021

China steps up measures to protect capital Beijing, reports 107 new cases

BEIJING - China stepped up measures to protect this capital city, as an uptick in coronavirus cases driven by the more infectious Delta variant spread across multiple cities in the country.

The National Health Commission reported on Saturday 107 new confirmed coronavirus cases in the mainland for Aug. 6, compared with 124 a day earlier.

Of the new infections, 75 were locally transmitted, the health authority said. That compares with 80 local cases a day earlier. Most of the local cases were in the eastern province of Jiangsu.

Those currently outside Beijing in higher risk areas should temporarily postpone their return, and others should provide a negative COVID-19 test, according to details of a Saturday meeting by local officials reported by the Beijing Daily. Epidemic prevention measures at railways, highways and airports should be strengthened, they said.

Some local governments have been called out by Beijing for lowering their guard, leading to the spread of the Delta variant from multiple sources.

To deal with the infections, some cities have initiated multiple rounds of mass testing to identify carriers. Inter-city travel restrictions have been imposed, and public places of gathering including entertainment venues have been either shut or restricted.

But a health official said last week he expected China's latest outbreak to be largely under control within weeks.

China reported 32 new asymptomatic coronavirus cases, which it does not classify as confirmed infections, compared with 58 a day earlier.

No new deaths were reported.

As of Aug. 6, mainland China had recorded 93,605 confirmed cases, with the cumulative death toll unchanged at 4,636. (Reporting by Gabriel Crossley; Editing by Jacqueline Wong)

-reuters

Tuesday, August 3, 2021

US stocks edge down on virus woes, slowing economy

NEW YORK - The S&P 500 Index closed slightly lower on Monday after erasing early gains as worries about the Delta variant of the coronavirus and a slowing US economy overshadowed optimism around more fiscal stimulus and a strong second-quarter earnings season.

Federal Reserve Governor Christopher Waller said on CNBC late in the session that the Fed could start to reduce its support for the economy by October if the next two monthly jobs reports each show employment rising by 800,000 to 1 million, as he expects. 

He also suggested the Fed could announce in September it would start to reduce its monthly bond purchases, which could lift yields again - not the best news for the stock market. 

Data earlier in the day showed that although US manufacturing grew in July, its pace slowed for a second straight month as spending rotated back to services from goods, and shortages of raw materials persisted. 

The softer-than-expected data also sent US bond yields to their lowest since July 20 and knocked the blue-chip Dow off an intra-day record high hit in early trading. 

“An issue for the market... is the rise of the growth scare", said Rob Haworth, senior investment strategist at US Bank, "Whether it's more restrictions in China with infections rising in 14 provinces now, or questions about how far is the US going to have to go with mask mandates.”

Only four of the 11 S&P sectors traded higher by market close, among them utilities and real estate generally considered safe bets at a time of uncertainty.

The Dow Jones Industrial Average fell 97.31 points, or 0.28 percent, to 34,838.16, the S&P 500 lost 8.1 points, or 0.18 percent, to 4,387.16 and the Nasdaq Composite added 8.39 points, or 0.06 percent, to 14,681.07. Square Inc, the payments firm of Twitter Inc co-founder Jack Dorsey, jumped after it said it would purchase Australian buy now, pay later pioneer Afterpay Ltd for $29 billion. 

With manufacturing activity data coming in weaker than expected, investor focus now turns to services sector data on Wednesday and the Labor Department's monthly jobs report on Friday.

After mixed quarterly reports from technology behemoths last week, all eyes this week are on earnings from companies including Eli Lilly and Co, CVS Health Corp and General Motors Co.

Volume on US exchanges was 8.80 billion shares, compared with the 9.77 billion average for the full session over the last 20 trading days. 

Declining issues outnumbered advancing ones on the NYSE by a 1.07-to-1 ratio; on Nasdaq, a 1.05-to-1 ratio favored advancers.

The S&P 500 posted 76 new 52-week highs and 2 new lows; the Nasdaq Composite recorded 98 new highs and 67 new lows.

-reuters

Friday, July 2, 2021

Johnson and Johnson says COVID-19 vaccine effectively combats Delta variant

WASHINGTON - Johnson and Johnson's single-shot COVID-19 vaccine is effective against the highly contagious Delta variant, with an immune response lasting at least 8 months, the company said Thursday.

The antibodies and immune system cells in the blood of 8 people vaccinated with the J&J jab effectively neutralized the Delta strain, which was first identified in India, researchers found.

A second study with 20 vaccinated patients at Boston's Beth Israel Medical Center had similar results.

The data was sent to bioRxiv, a free online site for unpublished scientific preprints where authors "are able to make their findings immediately available to the scientific community and receive feedback on draft manuscripts before they are submitted to journals," according to the site.

"We believe that our vaccine offers durable protection against COVID-19 and elicits neutralizing activity against the Delta variant," said Paul Stoffels, J&J's chief scientific officer, in a company statement.

Mathai Mammen, head of Janssen Research & Development at Johnson & Johnson, said that data "for the 8 months studied so far" shows that J&J's single-shot vaccine "generates a strong neutralizing antibody response that does not wane; rather, we observe an improvement over time."

The Delta variant tore through in India in April and May and has since spread around the world. A report by the European Union's disease control agency ECDC estimated the more contagious strain could account for 90 percent of new cases in the EU by the end of August.

Agence France-Presse